SCHEMBL5835573

SCHEMBL5835573

CN1CC[C@@H](Oc2cc(NS(=O)(=O)c3ccc(C#N)cc3Cl)ccc2Cl)C1

nearest known ligand 0.64

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
UTS2R Q9UKP6 9/20 0.64
BRPF1 P55201 3/20 0.42
BRD1 O95696 2/20 0.42
BRD9 Q9H8M2 2/20 0.42
BRPF3 Q9ULD4 2/20 0.42
TRIM24 O15164 1/20 0.42
BRD4 O60885 1/20 0.42
BRD7 Q9NPI1 1/20 0.42
PIK3C3 Q8NEB9 1/20 0.41
SLC22A12 Q96S37 1/20 0.40
HTR6 P50406 2/20 0.39
CYP3A4 P08684 1/20 0.39
PPARG P37231 1/20 0.39
DRD2 P14416 1/20 0.39
HTR2A P28223 1/20 0.39
HTR2C P28335 1/20 0.39
DRD3 P35462 1/20 0.39
CYP19A1 P11511 1/20 0.39
TRPV4 Q9HBA0 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5835577 1.00 UTS2R (0.64) UTS2RBRPF1BRD1BRD9BRPF3
SCHEMBL8342093 0.87 UTS2R (0.69) UTS2RPPARGHTR2C
SCHEMBL8338821 0.85 UTS2R (0.67) UTS2RBRD4HTR6HTR2C
SCHEMBL5835483 0.85 UTS2R (0.72) UTS2RHTR6
SCHEMBL5835487 0.85 UTS2R (0.72) UTS2RHTR6
SCHEMBL6817499 0.84 UTS2R (0.69) UTS2RBRPF1BRD1BRD9BRPF3
SCHEMBL6817509 0.84 UTS2R (0.69) UTS2RBRPF1BRD1BRD9BRPF3
SCHEMBL5834952 0.84 UTS2R (0.71) UTS2RHTR6
SCHEMBL5834957 0.84 UTS2R (0.71) UTS2RHTR6
SCHEMBL6709227 0.83 UTS2R (0.55) UTS2RSLC22A12HTR6CYP3A4PPARG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7026349-B2 Sulfonamides SMITHKLINE BEECHAM CORPORATION (US) 2006-04-11 US claimed
US-20040152906-A1 Sulfonamides SHELL OIL COMPANY 2004-08-05 US claimed
US-7026349-B2 Sulfonamides SMITHKLINE BEECHAM CORPORATION (US) 2006-04-11 US disclosed
EP-1385507-A4 SULFONAMIDES SMITHKLINE BEECHAM CORP (US) 2005-11-23 EP disclosed
US-20040152906-A1 Sulfonamides SHELL OIL COMPANY 2004-08-05 US disclosed
EP-1385507-A1 SULFONAMIDES SmithKline Beecham Corporation (US) 2004-02-04 EP disclosed
WO-2002089792-A1 SULFONAMIDES SMITHKLINE BEECHAM CORPORATION (US) 2002-11-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040152906-A1 Sulfonamides UTS2R, PRSS2, STS UTS2R 1/4885BRPF1 2974/4885BRD1 2738/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.